tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Context Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsContext Therapeutics Reports Q2 2025 Financial Results
1M ago
Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
Premium
The Fly
Context Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
2M ago
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
Premium
The Fly
Context Therapeutics reports Q2 EPS (9c), consensus (5c)
2M ago
Promising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
PremiumRatingsPromising Progress in Context Therapeutics’ Cancer Treatment Advances: Buy Rating Affirmed
5M ago
Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
Premium
Ratings
Optimistic Buy Rating on Context Therapeutics Amid Promising Program Developments and Undervaluation
5M ago
Context Therapeutics CMO Claudio Dansky Ullmann to depart
Premium
The Fly
Context Therapeutics CMO Claudio Dansky Ullmann to depart
5M ago
Context Therapeutics Begins Phase 1 Trial for CT-95
PremiumCompany AnnouncementsContext Therapeutics Begins Phase 1 Trial for CT-95
6M ago
Context Therapeutics doses first patient in Phase 1 trial of CT-95
Premium
The Fly
Context Therapeutics doses first patient in Phase 1 trial of CT-95
6M ago
Context Therapeutics: 2024 Financial and Strategic Highlights
Premium
Company Announcements
Context Therapeutics: 2024 Financial and Strategic Highlights
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100